COMMUNIQUÉS West-GlobeNewswire

Alabama Attorney General Steve Marshall Champions The Helios Alliance's Project RenewAL to Advance Statewide Opioid Abatement
31/03/2026
Building on proven success in southwest Alabama, the partnership will assist cities and counties across the State in spending opioid settlement resources effectively — with local leadership, regional cooperation, and [...]
ZymoChem's BAYSE™ Becomes First Bio-Based Superabsorbent to Match and Outperform Petroleum-Based Materials
31/03/2026
New research paper reveals breakthrough performance data and successful consumer trials for a biodegradable alternative to the plastics at the heart of billions of diapers, period products, and incontinence pads [...]
Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year 2025
31/03/2026
PLAINVIEW, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and IT services, professional sales services, and [...]
Global Medtech CDMO Market Grows to $96.5B in 2025 as Pharma-Medtech Convergence Emerges as a Defining Accelerator
31/03/2026
Alira Health’s annual CDMO medtech report highlights growth, consolidation, and capability expansion; market projected to reach $143.6B by 2030 at an 8.3% CAGR FRAMINGHAM, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Alira [...]
EssilorLuxottica et Meta élargissent leur portefeuille de lunettes IA avec les modèles Ray-Ban Meta optiques
31/03/2026
EssilorLuxottica et Meta élargissent leur portefeuille de lunettes IA avec les modèles Ray-Ban Meta optiques Paris, France et Menlo Park, USA (31 mars 2026) – EssilorLuxottica et Meta annoncent l'expansion de leur [...]
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
31/03/2026
Model estimates SUBLOCADE ® may reduce staff time and associated costs compared with other medications for opioid use disorder in jails and prisons RICHMOND, Va., March 31, 2026 (GLOBE NEWSWIRE) -- Indivior [...]
Berry Street Joins Amazon's Health Benefits Connector, Expanding Access to one of Healthcare's Most Underutilized Benefits
31/03/2026
Amazon customers can now discover and enroll in Berry Street's evidence-based nutrition care for weight loss, 30+ conditions NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Berry Street , an AI-powered nutrition therapy [...]
LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program
31/03/2026
Delivering up to $1,200 in annual patient savings on branded GLP-1 therapy, expanding LifeMD’s collaboration with Novo Nordisk NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider [...]
IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study
31/03/2026
IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer Final Phase 2 clinical data show [...]
electroCore Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
31/03/2026
ROCKAWAY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Seth Abrams will join [...]
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
31/03/2026
SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant [...]
Proxygen Appoints Chiara Conti, Ph.D. as Chief Scientific Officer to Drive Clinical Translation and Expand Induced Proximity Platform Beyond Degradation
31/03/2026
Vienna, Austria, March 31, 2026 (GLOBE NEWSWIRE) -- Vienna, Austria, March 31, 2026 - Proxygen, a biotechnology company pioneering the discovery of molecular glue degraders and next-generation proximity-based [...]
Adcytherix Doses First Patient in Phase 1 Trial of ADCX-020 and Strengthens Leadership to Support Next Phase of Growth
31/03/2026
Adcytherix Doses First Patient in Phase 1 Trial of ADCX-020 and Strengthens Leadership to Support Next Phase of Growth Initial patient dosed in the First-in-Human clinical trial of ADCX-020, marking Adcytherix’s [...]
Catheter Precision Reports 2025 Results and Updates on Strategic Expansion
31/03/2026
Clinical, Commercial and Regulatory Milestones Achieved in 2025 Establish a Strong Foundation in Life Sciences as Revenue Increases 95% Year Over Year Acquisition of Flyte and Strengthened Capital Position Unlock Multi- [...]
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
31/03/2026
Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028 Received FDA Fast Track designation for stenoparib, enabling accelerated [...]
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
31/03/2026
Fort Lee, NJ, March 31, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision [...]
Iantrek Advances New AlloSpan™ Canal into U.S. Site Evaluations, Expanding Its Bio-Interventional Platform
31/03/2026
Controlled early clinical adoption begins across select U.S. centers as Iantrek accelerates toward commercialization of its next-generation canal-based restoration technology WHITE PLAINS, N.Y., March 31, 2026 (GLOBE [...]
Solésence Reports Fourth Quarter and Full-Year 2025 Financial Results
31/03/2026
Full Year 2025 record revenue of $62.1 million ROMEOVILLE, Ill., March 31, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science [...]
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
31/03/2026
Encouraging Phase 2 HIT data and recent FDA feedback support continued advancement of CAD-1005 as Cadrenal’s near-term development priority; broader 12-LOX platform remains a longer-term opportunity PONTE VEDRA, Fla., [...]

Pages